Pituitary adenomas (PAs) are one of the most common intracranial tumors, which can result in significant morbidity and can cause mortality either by exerting central pressure effects from the pituitary mass or by secreting excessive pituitary hormones1. Depending on their capability to produce hormones, PAs are classified as clinically functioning and nonfunctioning (NF). Functioning PAs include 6 subtypes, characterized by hypersecretion of prolactin (PRL), growth hormone (GH), adrenocorticotropin (ACTH), gonadotropins including follicle stimulating hormone and luteinizing hormone (GT), thyrotropin (TSH) or multiple hormones (plurihormonal), respectively. We and other group recently reported the recurrent genetic mutations in ACTH-PAs2,3. Previous studies also identified genetic alterations in GH-PAs by whole-genome and -exome sequencing4,5 and in 7 NF-PAs by exome analysis6. Due to challenges in collection and preparation of PA samples, exome-wide sequencing of other subtypes, including the PRL-, GT-, TSH-, and plurihormonal PA subtypes, has not been reported yet. To provide a comprehensive genetic landscape of all 7 subtypes of PAs, we examined the somatic mutational landscape of 125 PAs, including 20 NF-PAs, 20 PRL-PAs, 20 GH-PAs, 20 ACTH-PAs, 20 GT-PAs, 10 TSH-PAs, and 15 plurihormonal PAs. Plurihormonal PAs in this series secreted GH+PRL (n = 11), GH+ACTH (n = 2), or GH+TSH (n = 2). The analysis of 20 ACTH-PAs included 12 tumor samples analyzed in our previous study2. The clinical characteristics of these patients are summarized in Supplementary information, Table S1A. The detailed methods are described in Supplementary information, Data S1 and Figure S1A. We identified 412 somatic mutations in 125 PAs (Supplementary information, Table S1B). This analysis confirmed a relatively low number of somatic mutations per tumor across all 7 PA subtypes (mean = 3.3 mutations per exome; Figure 1A)3,4,5,6. The predominant substitution was C>T/G>A transitions which accounted for 41% of all substitutions across all PA subtypes, followed by T>C/A>G transitions (23%), similar to other intracranial tumors (Supplementary information, Figure S1B). Recurrently-mutated genes are shown in Figure 1A. We confirmed mutations in G protein subunit α (GNAS), ubiquitin-specific protease 8 (USP8), Nuclear Receptor Subfamily 3 Group C Member 1 (NR3C1), and Menin 1 (MEN1) in PAs and identified new somatic variants in these genes. Activating mutations of GNAS have long been known to play a role in pathogenesis of GH-PAs7. In this study, GNAS mutations were identified in 54% of all GH-secreting tumors, including 8 of 20 GH-monosecreting tumors and 11 of 15 plurihormonal tumors that secreted GH and another hormone. The high frequency of GNAS mutations in GH-PAs is consistent with previous findings4. GNAS alterations included p.R201C (n = 14), p.R201H (n = 1), p.Q227L (n = 3) and a novel p.G49R (n = 1) mutation. USP8 is a deubiquitinating enzyme that protects growth factor receptors including EGFR from degradation. Highly frequent USP8 mutations in ACTH-PAs have been shown by our group and others2,3. In this study, USP8 mutations were identified in 11 out of 20 ACTH-PAs, among which all mutation types have been described previously2,3. We also identified novel truncation mutations in the glucocorticoid receptor gene NR3C1 in two ACTH-PAs that did not contain USP8 mutations: p.Q632X-p.S512fs and p.R714P-p.630_630del. This is consistent with previous findings implicating mutations targeting NR3C1 as an uncommon contributor to ACTH-PA pathogenesis2. We additionally identified two novel somatic loss-of-function mutations in MEN1, including c.208_214del:p.D70fs and c.G608A:p.W203X, both in plurihormonal PAs producing GH and PRL from patients without a history of familial MEN syndrome and without germline MEN1 mutations. While germline MEN1 mutations have long been linked to PAs, MEN1 mutations have also been reported as rare somatic events in sporadic PAs8. We also identified recurrently-mutated kinesin heavy chain isoform 5A (KIF5A) and growth factor receptor-bound protein 10 (GRB10) as novel targets in two PA patients, respectively. KIF5A is a member of the kinesin family of proteins, which participates in a multisubunit complex to promote intracellular organelle transport. Somatic KIF5A mutations are found in prostate cancer9, but had not been linked to PAs. We identified somatic mutations targeting the stalk (p.Y749C) and tail (p.T938I) domains of KIF5A in two PAs. GRB10 encodes an intracellular adapter protein which interacts with several receptor tyrosine kinases and downstream signaling molecules to regulate secretion of insulin and other peptides10. We identified novel mutations in GRB10 including p.L357F and p.T155S, both in GH-PAs (2 out of 20 GH-PAs, 10%), one of which also contained a GNAS mutation, while the other one did not. GRB10 mutations in GH-PAs implicate GRB10 in the pathogenesis of GH-PAs. In addition, mutations of other genes, such as IARS, SP100 and TRIP12, occurred in two cases (Figure 1A). We next focused on somatic copy number alternations (SCNA) in our panel of 125 PAs (Supplementary information, Figure S1C). We found that 18% (22/125) of samples had SCNA involving < 10% of the genome; and 32% (40/125) had considerably greater levels of genomic disruption, with > 80% of the genome involved. We observed frequent loss of chromosomes 11q13.2 (q-value = 1.01E-18) and 11p15.5 (q-value = 1.14E-16), consistent with the previous study11. We also observed loss of 1p36.31 (q-value = 1.0098E-18), 9q34.11 (q-value = 2.39E-18), 16p13.3 (q-value = 5.82E-18), and 3p21.31 (q-value = 1.34E-17), and frequent gain of 20q13.33 (q-value = 1.47E-29), 3p22.3 (q-value = 3.10E-22), 1q31.3 (q-value = 5.06E-18), 7q21.11 (q-value = 1.54E-17), and 16q12.2 (q-value = 2.59E-21). Our copy number data revealed frequent gains in regions encoding cohesin complex genes including synaptonemal complex genes SYCP1 on...